Among a variety of solid carcinomas, EIF4E2 is considered to be a valuable biomarker for distinguishing metastatic cancer from primary tumors (Ramaswamy et al., 2003). This evidence concerns the gene EIF4E2 and metastatic malignant neoplasm.